NCT06386003View on ClinicalTrials.gov

Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

May 31, 2025

Conditions
Post Traumatic Stress DisorderPTSDChronic PTSD
Interventions
DRUG

Psilocybin

Participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days.

Trial Locations (1)

Unknown

St. Michael's Hospital, Unity Health Toronto, Toronto

All Listed Sponsors
collaborator

Toronto Metropolitan University

OTHER

collaborator

University of Ottawa

OTHER

lead

Unity Health Toronto

OTHER

NCT06386003 - Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD | Biotech Hunter | Biotech Hunter